Literature DB >> 21570209

On the benefits and risks of proton therapy in pediatric craniopharyngioma.

Chris Beltran1, Monica Roca, Thomas E Merchant.   

Abstract

PURPOSE: Craniopharyngioma is a pediatric brain tumor whose volume is prone to change during radiation therapy. We compared photon- and proton-based irradiation methods to determine the effect of tumor volume change on target coverage and normal tissue irradiation in these patients. METHODS AND MATERIALS: For this retrospective study, we acquired imaging and treatment-planning data from 14 children with craniopharyngioma (mean age, 5.1 years) irradiated with photons (54 Gy) and monitored by weekly magnetic resonance imaging (MRI) examinations during radiation therapy. Photon intensity-modulated radiation therapy (IMRT), double-scatter proton (DSP) therapy, and intensity-modulated proton therapy (IMPT) plans were created for each patient based on his or her pre-irradiation MRI. Target volumes were contoured on each weekly MRI scan for adaptive modeling. The measured differences in conformity index (CI) and normal tissue doses, including functional sub-volumes of the brain, were compared across the planning methods, as was target coverage based on changes in target volumes during treatment.
RESULTS: CI and normal tissue dose values of IMPT plans were significantly better than those of the IMRT and DSP plans (p < 0.01). Although IMRT plans had a higher CI and lower optic nerve doses (p < 0.01) than did DSP plans, DSP plans had lower cochlear, optic chiasm, brain, and scanned body doses (p < 0.01). The mean planning target volume (PTV) at baseline was 54.8 cm(3), and the mean increase in PTV was 11.3% over the course of treatment. The dose to 95% of the PTV was correlated with a change in the PTV; the R(2) values for all models, 0.73 (IMRT), 0.38 (DSP), and 0.62 (IMPT), were significant (p < 0.01).
CONCLUSIONS: Compared with photon IMRT, proton therapy has the potential to significantly reduce whole-brain and -body irradiation in pediatric patients with craniopharyngioma. IMPT is the most conformal method and spares the most normal tissue; however, it is highly sensitive to target volume changes, whereas the DSP method is not.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21570209      PMCID: PMC3554244          DOI: 10.1016/j.ijrobp.2011.01.005

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  11 in total

1.  A conformation number to quantify the degree of conformality in brachytherapy and external beam irradiation: application to the prostate.

Authors:  A van't Riet; A C Mak; M A Moerland; L H Elders; W van der Zee
Journal:  Int J Radiat Oncol Biol Phys       Date:  1997-02-01       Impact factor: 7.038

2.  Secondary neutron dose during proton therapy using spot scanning.

Authors:  Uwe Schneider; Stefano Agosteo; Eros Pedroni; Jürgen Besserer
Journal:  Int J Radiat Oncol Biol Phys       Date:  2002-05-01       Impact factor: 7.038

3.  Phase II trial of conformal radiation therapy for pediatric patients with craniopharyngioma and correlation of surgical factors and radiation dosimetry with change in cognitive function.

Authors:  Thomas E Merchant; Erin N Kiehna; Larry E Kun; Raymond K Mulhern; Chenghong Li; Xiaoping Xiong; Frederick A Boop; Robert A Sanford
Journal:  J Neurosurg       Date:  2006-02       Impact factor: 5.115

4.  Potential reduction of the incidence of radiation-induced second cancers by using proton beams in the treatment of pediatric tumors.

Authors:  Raymond Miralbell; Antony Lomax; Laura Cella; Uwe Schneider
Journal:  Int J Radiat Oncol Biol Phys       Date:  2002-11-01       Impact factor: 7.038

5.  Inter- and intrafractional positional uncertainties in pediatric radiotherapy patients with brain and head and neck tumors.

Authors:  Chris Beltran; Matthew J Krasin; Thomas E Merchant
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-06-03       Impact factor: 7.038

Review 6.  Radiation therapy in the management of pediatric craniopharyngiomas--a review.

Authors:  John A Kalapurakal
Journal:  Childs Nerv Syst       Date:  2005-06-17       Impact factor: 1.475

Review 7.  Brain tumors across the age spectrum: biology, therapy, and late effects.

Authors:  Thomas E Merchant; Ian F Pollack; Jay S Loeffler
Journal:  Semin Radiat Oncol       Date:  2010-01       Impact factor: 5.934

8.  Surveillance of craniopharyngioma cyst growth in children treated with proton radiotherapy.

Authors:  Karen M Winkfield; Claudia Linsenmeier; Torunn I Yock; P Ellen Grant; Beow Y Yeap; William E Butler; Nancy J Tarbell
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-03-01       Impact factor: 7.038

9.  Cytokine and growth factor responses after radiotherapy for localized ependymoma.

Authors:  Thomas E Merchant; Chenghong Li; Xiaoping Xiong; M Waleed Gaber
Journal:  Int J Radiat Oncol Biol Phys       Date:  2008-11-18       Impact factor: 7.038

10.  Craniopharyngiomas: a clinicopathological analysis of factors predictive of recurrence and functional outcome.

Authors:  H L Weiner; J H Wisoff; M E Rosenberg; M J Kupersmith; H Cohen; D Zagzag; T Shiminski-Maher; E S Flamm; F J Epstein; D C Miller
Journal:  Neurosurgery       Date:  1994-12       Impact factor: 4.654

View more
  30 in total

Review 1.  Pediatric Craniopharyngiomas: A Primer for the Skull Base Surgeon.

Authors:  Christopher Salvatore Graffeo; Avital Perry; Michael J Link; David J Daniels
Journal:  J Neurol Surg B Skull Base       Date:  2018-01-19

2.  Radiotherapy for craniopharyngioma.

Authors:  Ajay Aggarwal; Naomi Fersht; Michael Brada
Journal:  Pituitary       Date:  2013-03       Impact factor: 4.107

Review 3.  Proton therapy for the treatment of children with CNS malignancies.

Authors:  Radhika Sreeraman; Daniel J Indelicato
Journal:  CNS Oncol       Date:  2014-03

4.  A reformed surgical treatment modality for children with giant cystic craniopharyngioma.

Authors:  Wanchun Zhu; Xiang Li; Jintao He; Tao Sun; Chunde Li; Jian Gong
Journal:  Childs Nerv Syst       Date:  2017-06-07       Impact factor: 1.475

5.  Radiological and clinical results following high-dose intensity-modulated radiotherapy in recurrent craniopharyngioma: A case report.

Authors:  Antonio Pierro; Savino Cilla; Vincenzo Picardi; Marica Ferro; Gabriella Macchia; Francesco Deodato; Milly Buwenge; Giuseppina Sallustio; Alessio G Morganti
Journal:  Oncol Lett       Date:  2015-07-20       Impact factor: 2.967

Review 6.  Clinical controversies: proton therapy for pediatric tumors.

Authors:  Thomas E Merchant
Journal:  Semin Radiat Oncol       Date:  2013-04       Impact factor: 5.934

7.  Proton beam therapy versus conformal photon radiation therapy for childhood craniopharyngioma: multi-institutional analysis of outcomes, cyst dynamics, and toxicity.

Authors:  Andrew J Bishop; Brad Greenfield; Anita Mahajan; Arnold C Paulino; M Fatih Okcu; Pamela K Allen; Murali Chintagumpala; Lisa S Kahalley; Mary F McAleer; Susan L McGovern; William E Whitehead; David R Grosshans
Journal:  Int J Radiat Oncol Biol Phys       Date:  2014-07-19       Impact factor: 7.038

8.  Evaluation of children with craniopharyngioma using carbon-11 methionine PET prior to proton therapy.

Authors:  Benjamin S Laser; Thomas E Merchant; Daniel J Indelicato; Chia-Ho Hua; Barry L Shulkin; Scott E Snyder
Journal:  Neuro Oncol       Date:  2013-02-13       Impact factor: 12.300

9.  Clinical outcomes following proton therapy for adult craniopharyngioma: a single-institution cohort study.

Authors:  Michael S Rutenberg; Ronny L Rotondo; Dinesh Rao; Adam L Holtzman; Daniel J Indelicato; Soon Huh; Christopher G Morris; William M Mendenhall
Journal:  J Neurooncol       Date:  2020-02-21       Impact factor: 4.130

10.  Recommendations for the referral of patients for proton-beam therapy, an Alberta Health Services report: a model for Canada?

Authors:  S Patel; X Kostaras; M Parliament; I A Olivotto; R Nordal; K Aronyk; N Hagen
Journal:  Curr Oncol       Date:  2014-10       Impact factor: 3.677

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.